NCT07117630View on ClinicalTrials.gov

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Breast Cancer
Interventions
DRUG

L-Ornithine L-Aspartate

3g orally three times daily

DRUG

Dalpiciclib

150mg orally once daily (3 weeks on/1 week off per 28-day cycle)

DRUG

Fulvestrant

500mg IM on Days 1 \& 15 of Cycle 1, then Day 1 of subsequent cycles

All Listed Sponsors
lead

Fudan University

OTHER